The statement 'Under the second-tier compliance regulations, 21 CFR Part 50 Subpart B addresses detailed requirements for informed consent' is true.

The statement 'Under the second-tier compliance regulations, 21 CFR Part 50 Subpart B addresses detailed requirements for informed consent' is true.

• A. True
• B. False
• C. Not applicable
• D. Partially True

Answer: (A)

At the heart of this item is recognizing that pediatric protections are built into FDA rules as a focused add-on to the general informed consent requirements. 21 CFR Part 50 Subpart B specifically addresses how informed consent is obtained when research involves children, providing the detailed, child-specific procedures beyond the baseline rules. It defines who can give permission for a child (a parent or guardian) and when the child’s assent should be sought, along with guidance on presenting information in an age-appropriate way and documenting both parental permission and the child’s assent. In other words, this subpart tightens and elaborates the consent process in pediatric research, layering extra protections on top of the general consent framework. Therefore, the statement is true.

At the heart of this item is recognizing that pediatric protections are built into FDA rules as a focused add-on to the general informed consent requirements. 21 CFR Part 50 Subpart B specifically addresses how informed consent is obtained when research involves children, providing the detailed, child-specific procedures beyond the baseline rules. It defines who can give permission for a child (a parent or guardian) and when the child’s assent should be sought, along with guidance on presenting information in an age-appropriate way and documenting both parental permission and the child’s assent. In other words, this subpart tightens and elaborates the consent process in pediatric research, layering extra protections on top of the general consent framework. Therefore, the statement is true.